News | March 18, 2022
AstraZeneca launches global R&D post-doctoral challenge
Successful proposals will secure fully funded postdoctoral research positions
Successful proposals will secure fully funded postdoctoral research positions
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Machine learning approach to systems biology combined with ligand discovery platform
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Subscribe To Our Newsletter & Stay Updated
